CW Advisors LLC Has $10.52 Million Stock Position in Abbott Laboratories $ABT

CW Advisors LLC increased its stake in shares of Abbott Laboratories (NYSE:ABT) by 41.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 77,317 shares of the healthcare product maker’s stock after purchasing an additional 22,536 shares during the period. CW Advisors LLC’s holdings in Abbott Laboratories were worth $10,516,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Twin Peaks Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter valued at about $177,000. Nicolet Bankshares Inc. grew its holdings in Abbott Laboratories by 4.2% during the second quarter. Nicolet Bankshares Inc. now owns 24,284 shares of the healthcare product maker’s stock valued at $3,303,000 after purchasing an additional 986 shares during the period. River Wealth Advisors LLC increased its stake in Abbott Laboratories by 8.3% in the second quarter. River Wealth Advisors LLC now owns 5,463 shares of the healthcare product maker’s stock valued at $743,000 after purchasing an additional 419 shares in the last quarter. Groupe la Francaise raised its holdings in Abbott Laboratories by 121.0% in the second quarter. Groupe la Francaise now owns 15,494 shares of the healthcare product maker’s stock worth $2,118,000 after purchasing an additional 8,482 shares during the period. Finally, Pinkerton Wealth LLC boosted its position in shares of Abbott Laboratories by 1.8% during the second quarter. Pinkerton Wealth LLC now owns 38,418 shares of the healthcare product maker’s stock worth $5,225,000 after purchasing an additional 692 shares in the last quarter. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Trading Up 0.1%

NYSE ABT opened at $125.39 on Friday. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23. The company has a debt-to-equity ratio of 0.23, a quick ratio of 1.24 and a current ratio of 1.70. The stock’s 50 day moving average price is $128.71 and its two-hundred day moving average price is $130.90. The stock has a market capitalization of $218.04 billion, a price-to-earnings ratio of 15.71, a PEG ratio of 2.28 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share for the quarter, hitting the consensus estimate of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The business’s quarterly revenue was up 6.9% on a year-over-year basis. During the same period last year, the business earned $1.21 EPS. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 earnings per share for the current fiscal year.

Abbott Laboratories Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, November 17th. Shareholders of record on Wednesday, October 15th were given a dividend of $0.59 per share. The ex-dividend date of this dividend was Wednesday, October 15th. This represents a $2.36 annualized dividend and a yield of 1.9%. Abbott Laboratories’s payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

ABT has been the topic of several research analyst reports. The Goldman Sachs Group raised their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a research note on Wednesday, October 1st. Barclays raised their price target on Abbott Laboratories from $159.00 to $162.00 and gave the stock an “overweight” rating in a research report on Friday, October 17th. Daiwa Capital Markets boosted their price objective on Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research report on Tuesday, October 21st. Royal Bank Of Canada restated an “outperform” rating and set a $147.00 target price on shares of Abbott Laboratories in a report on Thursday, October 16th. Finally, Raymond James Financial upped their price target on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a report on Thursday, October 16th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $147.00.

Abbott Laboratories Company Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.